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Available online 27 February 2016Background: Identifying migraineurs by triptan utilization we studied risk for stroke inmigraineurs compared to
the general population.
Methods: A cohort study including all citizens 25–80 years of age in Denmark 2003–2011 was conducted. All
persons prescribed triptans, and all those hospitalized for a ﬁrst stroke were identiﬁed in the Danish Registries.
Information on stroke severity/subtype and cardiovascular risk factors was available for stroke patients.
Findings:Of the 49,711 patients hospitalized for a ﬁrst stroke, 1084weremigraineurs using triptans. Adjusting for
age, sex, income, and educational level, risk for strokewas higher amongmigraineurs in respect to all strokes (RR
1.07; CI 1.01–1.14) and ischemic strokes (RR 1.07; CI 1.00–1.14). Risk for hemorrhagic stroke was increased but
only in women (RR 1.41; CI 1.11–1.79). Risk was for mild strokes (RR 1.31; CI 1.16–1.48) while risk for severe
strokes was lower among migraineurs (RR 0.77; CI 0.65–0.91). Risk was age-related; highest among women
25–45 years (RR≈ 1.7). Risk was unrelated to numbers of dispensations.
Interpretation:Migraineurs identiﬁedby triptanutilization hadhigher risk for stroke. Strokeswereminor and car-
diovascular risk factors were less prevalent pointing to a migraine-speciﬁc etiology of stroke different from that
of thromboembolism.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Migraine is associated with a two-fold increased relative risk for
stroke (Etminan et al., 2005; Schurks et al., 2009; Spector et al., 2010).
Etiology of stroke in migraine remains still obscure (Kurth and Diener,
2012). It is not known whether it is thromboembolic or migraine-
speciﬁc being different from that of thromboembolism (Kurth and
Diener, 2012). Studies relate migraine to hemorrhagic stroke but they
are too few and too small to make conclusions about etiology (Sacco
et al., 2013; Kurth and Tzourio, 2013).
The reason for our insufﬁcient knowledge on stroke inmigraineurs is
in part that the increased risk in absolute terms is small and available
studies on the risk for stroke among migraineurs are hampered by
small numbers weakening the reliability of risk estimations (Kurth
and Diener, 2012).
As an alternative way of establishing a sizeable cohort of migraine
patients with stroke we identiﬁed migraine through triptan utilization.
Based on this cohort the purpose of this study was to estimate risk of
stroke and to characterize strokes by age, sex, subtype and severity iny, DK-2400 Copenhagen, NV,
. This is an open access article underthe population of Danes with migraine who had been prescribed
triptans.
2. Methods
The design of this studywas based on the idea of establishing a large
cohort of migraine patients identiﬁed by triptan utilization.
The study is a cohort study on all Danes aged 25–80 years who lived
in Denmark during some or all of the period between January 1, 2003
and December 31, 2011. The cohort was linked to the Danish registries
by the unique personal identiﬁcation number to obtain information on
triptan use, strokes and confounders (i.e. education and disposable
income).
In Denmark triptans need prescription by a physician. Information
on prescriptions for triptans (ATC-code N02CC) and numbers of pre-
scriptions dispensedwas obtained from theDanish Registry of Prescrip-
tions. In Denmark triptans cannot be dispensed without prescription by
an authorized physician. A prescription is reported in the Danish Regis-
try of Prescriptions only if the patient buys the prescribedmedication in
any pharmacy in Denmark.
Information on hospitalization for stroke was obtained from the
Danish Stroke Registry (Olsen et al., 2007; Mainz et al., 2004). Stroke
was deﬁned according to World Health Organization criteria (Reportthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1989) andwe included incident hospital admissions forﬁrst-ever stroke
(ischemic or hemorrhagic; ICD-10 codes I61 and I63) in the period
2003–2011. For patients with multiple hospital admissions, only the
ﬁrst admission was included. Transient ischemic attacks were not in-
cluded in the Registry. Patients aged b25 and N80 years were excluded
from the study, as well as patients for whom scanning was not per-
formed (0.4%)/result not available (0.7%). Most stroke patients (90%)
are admitted to hospital, as access to hospital care is free in Denmark
(Jørgensen et al., 1992). Information on education and disposable in-
come for the cohort was obtained from Statistics Denmark (Dalton
et al., 2008); both variables are associated with incidence of stroke
and to some level proxies for lifestyle factors such as smoking (Dalton
et al., 2008). Education was grouped into three categories: basic/high
school (7–12 years of primary, secondary, and grammar-school educa-
tion); vocational (10–12 years of education including vocational train-
ing); and higher (≥13 years of education) (Dalton et al., 2008). People
for whom information on education was missing were excluded
(14%). Disposable income was deﬁned as household income after taxa-
tion and interest per person, adjusted for the number of people in the
household and deﬂated according to the 2000 value of the Danish
crown (DKK). For the analyses, disposable income was categorized
into the 20th, 40th, 60th, and 80th percentiles of the age and gender-
speciﬁc income distribution.
To study the association between migraine (identiﬁed through trip-
tan utilization) and the risk factor proﬁle among stroke patients, we in-
cluded information fromDanish Stroke Registry. These data include age,
sex, stroke severity on admission measured on the Scandinavian stroke
scale (Lindenstrøm et al., 1991), stroke subtype (ischemic/hemorrhag-
ic) and cardiovascular proﬁle. The Scandinavian stroke scale is a validat-
ed neurological scale of stroke severity from 0 to 58, lower scores
indicating more severe strokes (Lindenstrøm et al., 1991). Ischemic
strokewasdistinguished fromhemorrhagic stroke by computed tomog-
raphy or magnetic resonance scanning. The cardiovascular proﬁle (only
available for the stroke patients) included information on alcohol con-
sumption (under/over the limit set by the Danish National Board of
Health) and current daily smoking. Diabetes mellitus, atrial ﬁbrillation
(chronic or paroxystic), arterial hypertension, previous myocardial
infarction, previous stroke, and intermittent arterial claudication were
diagnosed according to current Danish standards (Mainz et al., 2004).
The study protocol was approved by the board of the Danish Stroke
Registry and the Danish Data Protection Agency (journal number 2012-
41-0719).
2.1. Statistics
We conducted a prospective analysis of the entire Danish population
aged 25–80 in the period 2003–2011 and estimated the association be-
tween migraine identiﬁed through triptan utilization and risk of hospi-
talization for stroke. The cohort was tabulated in grouped-data format,
so that data were collapsed into strata, with one stratum for each com-
bination of the available covariates (i.e. sex, age, calendar year, educa-
tion, disposable income, and triptan use). Each stratum provided the
total number of strokes and total follow-up time (person-year) at risk.
Associations between migraine identiﬁed through triptan utilization
and stroke was estimated with Poisson regression models (McCullagh
and Nelder, 1989) and effect estimates are presented as relative risks
(RRs) with 95% conﬁdence intervals (CIs). Triptan use was calculated
from the number of packages prescribed during the ﬁve years before
the stroke and was then categorized into: no use and use of at least
one package in the previousﬁve years. Themodelswere adjusted for in-
come and education the year before the stroke, calendar year, sex, and
age (modeled as a restricted cubic spline with four knots) the year of
the stroke. Following the overall analysis, subanalyses were undertaken
considering subtypes of strokes as outcome, i.e. ischemic strokes, hem-
orrhagic strokes and stroke severity categorized by quartile on theScandinavian scale (0–37, 38–50, 51–56, 57–58). As sensitivity analyses
we examined the effect of triptanusewithin one-year, two-years, three-
years, and four-years time window prior to index data and evaluated
triptan use the ﬁve years before stroke with the additional categoriza-
tion: no use, use of only a package, and use of two and more packages.
Furthermore, we examined the dose–response relationship between
number of prescriptions dispensed within the ﬁve-years and one-year
time window as a continuous and linear variable on the log incidence
rate.
The possible effect modiﬁcation of triptan use by age was evaluated
by testing the interaction between age and triptan use bymeans of like-
lihood ratio tests. The effect by age was then inspected visually for ease
of interpretation.We also evaluated the effectmodiﬁcation in the risk of
stroke in migraine identiﬁed through triptan utilization with respect to
ischemic stroke vs. hemorrhagic stroke and among stroke severity
categories.
We made additional subanalysis including only women between 25
and 50 years in order to study effect modiﬁcation by oral contraceptive
use (ATC-code G03A). The subanalysis was conducted by means of Cox
regression including use of oral contraception in addition to the other
adjustment variables in the main analysis. Oral contraceptive use was
deﬁned as ever/never use within each calendar year and allowed to
change status as time was progressing.
Finally, we described prevalence of risk factors in stroke patients by
triptan use. Differences in risk factor proﬁle between migraine patients
identiﬁed through triptan utilization and non-users of triptans were
evaluated by the inverse probability weights method to adjust for age
at stroke followed by Wald test (Cole and Hernán, 2004). All analyses
were conducted with R statistical software (R Core Team, 2013), and
0.05 was considered to represent statistical signiﬁcance.
3. Results
The participants contributed 32.923 million person–years to the
analysis; of these, triptan-users contributed 1.105 million person–
years. During the study period, 49,711 Danes aged 25–80 years were
registered in the Danish Stroke Register as having been hospitalized
for a ﬁrst stroke. Among these, 1084 had been prescribed triptans with-
in the past ﬁve-years prior to index date. Themean number of prescrip-
tions dispensed during ﬁve years was 22 packages (Inter quartile range
(IQR) 24 packages; 1st quartile: 4 packages; 3 quartile 28 packages).
Demographic data for users and non-users of triptans are presented
in Table 1. Triptan users were younger, more often women, and more
often belonged to low-income and short-education groups. The crude
incidence of hospitalization for stroke was 1.51 per 1000 per year for
non-users of triptans and 1.36 per 1000 per year for users.
The relation between age, sex and use of triptans is illustrated in
Fig. 1. Triptans were prescribed to 5% of women and 1.4% of men aged
25–80 years during the study period. Usage reached a maximum at
the age of 45–50 years (7·5% of women and 1·8% of men) and de-
creased rapidly with age after the end of the ﬁfties.
The relative risks for stroke among migraine patients identiﬁed
through triptan utilization are shown in Table 2. The risk was increased
for all strokes (RR 1.07; CI 1.01–1.14) and ischemic strokes (RR 1.07; CI
1.00–1.14) while not for hemorrhagic strokes (RR 1.18; CI 0·95–1.45).
Stratifying by sex the risk for all stroke and ischemic stroke was in-
creased in both sexes There was an increased risk for hemorrhagic
stroke in women (RR 1.41; CI 1.11–1.80) but not in men. Test for effect
modiﬁcation in risk of stroke with respect to triptan use for ischemic
versus hemorrhagic stroke showed no statistical signiﬁcant difference
(Table 2).
Overall the risk for severe strokewas lower amongmigrainepatients
identiﬁed through triptan utilization (RR 0.71; CI 0.65–0.91), while the
risk for mild stroke was higher (RR 1.31; CI 1.16–1.48). The relation be-
tween risk for stroke by age inmigraine patients identiﬁed through trip-
tan use is shown in Fig. 2. The estimated riskwas closely associatedwith
Table 1
Basic characteristics of the Danish population aged 25–80 years in the period 2003–2011 by triptan use.
Non-users Users
%a 105 person-years No. of events Incidence 102 person-yearsb %a 105 person-years No. of events Incidence 102 person-yearsb
All 318.18 48,627 1.51 11.05 1084 1.36
Sex Male 50.77 161.51 28,676 1.84 20.54 2.27 328 1.83
Female 49.23 156.67 19,951 1.20 79.46 8.78 756 1.22
Income (quintile) 1st 19.9 63.29 11,594 1.84 18.42 2.03 264 1.77
2nd 20.04 63.75 11,083 1.72 19.53 2.16 225 1.45
3rd 20.04 63.78 9754 1.51 19.82 2.19 214 1.50
4th 20.03 63.75 8653 1.34 20.46 2.26 196 1.30
5th 19.99 63.64 7543 1.17 21.77 2.41 185 0.95
Education Basic 10.74 34.20 1797 1.53 12.18 1.35 90 0.41
Vocational 61.08 194.28 38,468 1.17 55.56 6.14 741 1.07
Higher 25.56 81.43 7178 1.63 30.51 3.37 232 1.43
Unknown 2.62 8.33 1184 1.58 1.75 0.19 21 1.44
Age (years) ≤35 20.79 66.30 598 0.09 18.92 2.09 35 0.17
36–47 26.07 83.10 3110 0.37 33.87 3.74 209 0.56
48–61 27.98 89.08 12,223 1.37 34.08 3.77 434 1.15
≥62 25.16 79.70 32,696 4.10 13.13 1.45 406 2.81
a Percentages of non-users and users of triptan in the total population.
b Age-adjusted incidence with direct standardization by use of the whole Danish cohort as the reference population.
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creasing rapidly thereafter with no association with triptan use after
the age of about 55 years.
As a sensitivity analysis we examined the effect of triptan usewithin
one-year, two-years, three-years, and four-years time window prior to
index data.We found virtually no difference in effect estimates between
the analysis deﬁning exposure in one and ﬁve years' time. Also the addi-
tional categorization for triptan use (no use, use of one package, and use
of two and more packages) did not show different results in respect to
the main analysis. We examined the dose response effect by including
the number of prescriptions as a continuous variable along with the in-
dicator of triptan use. This parametrization of themodel allowed for es-
timation of RR per prescriptionwithin triptan users. Overall, we ﬁnd the
RR pertinent to the dose response relationship to be 0·99 (CI 0.98–1.01)
in women and 1.00 (CI 0.99–1.01) in men. Thus, we did not ﬁnd evi-
dence of a dose response relationship between number of prescriptions
for triptans on the risk of stroke, i.e. the RR associated with ever/never
use remained unchanged.
The cardiovascular risk factor proﬁle of stroke patients stratiﬁed by
triptan use is shown in Table 3. Table 4 shows the age-adjustedFig. 1. Percentages of triptan users by attained age and calendar year in the Danishprevalence of cardiovascular risk factors in stroke patients stratiﬁed by
use of triptans. The prevalence of cardiovascular risk factors was lower
among stroke patients with migraine identiﬁed through triptan
utilization.
There was no effect modiﬁcation of oral contraceptive (OC) use on
the effect of triptans in subanalysis including women between 25 and
50 years of age: 5.27% of women used triptans while using OC at the
same time compared to 5·44% using triptans while not using OC at
the same time. Running ourmodelwithout adjusting for oral contracep-
tives use risk of stroke among triptan users 25–50 years of age was HR
1·41 (CI 1.27–1.65); adjusting for oral contraceptives risk of stroke
among triptan users was HR 1·43 (CI 1.25–1.63).
4. Discussion
In this study of theDanish population duringnine years of follow-up,
based on the concept of identifyingmigraine through triptan utilization
the risk of being hospitalized for stroke was higher among migraineurs.
The risk was increased for all strokes and ischemic strokes, while for
hemorrhagic stroke risk was increased only in women. The strokes ofpopulation aged 25–80 years in the period 2003–2011; (a) males, (b) females.
Table 2
Relative risks (RRs) and 95% conﬁdence intervals (CIs) for triptan users versus non-users by stroke type in the complete data.
Stroke Triptan
General Male Female
No. of events
(105 person-years)
RRa (CI) No. of events
(105 person-years)
RRb (CI) No. of events
(105 person-years)
RRb (CI)
All Non-users 48,627 (318.18) Ref. 28,676 (161.51) Ref. 19,951 (156.67) Ref.
Users 1084 (11.05) 1.07 (1.01–1.14) 328 (2.27) 1.06 (0.95–1.19) 756 (8.78) 1.10 (1.02–1.18)
Ischemic Non-users 44,852 (318.18) Ref. 26,467 (161.51) Ref. 18,385 (156.67) Ref.
Users 993 (11.05) 1.07 (1.00–1.14) 310 (2.27) 1.09 (0.97–1.22) 683 (8.78) 1.07 (0.99–1.16)
Hemorrhagic Non-users 3775 (318.18) Ref. 2209 (161.51) Ref. 1566 (156.67) Ref.
Users 91 (11.05) 1.18 (0.95–1.45) 18 (2.27) 0.76 (0.48–1.21) 73 (8.78) 1.41 (1.11–1.80)
p-value† 0.44 0.11 0.08
Severity score
0–37 Non-users 9105 (318.18) Ref. 4971 (161.51) Ref. 4134 (156.67) Ref.
Users 145 (11.05) 0.71 (0.65–0.91) 40 (2.27) 0.75 (0.55–1.02) 105 (8.78) 0.73 (0.61–0.89)
38–50 Non-users 10,244 (318.18) Ref. 5994 (161.51) Ref. 4250 (156.67) Ref.
Users 201 (11.05) 0.95 (0.83–1.09) 65 (2.27) 1.01 (0.79–1.29) 136 (8.78) 0.93 (0.78–1.10)
51–56 Non-users 13,777 (318.18) Ref. 8371 (161.51) Ref. 5406 (156.67) Ref.
Users 342 (11.05) 1.20 (1.08–1.34) 110 (2.27) 1.22 (1.01–1.48) 232 (8.78) 1.24 (1.09–1.41)
57–58 Non-users 10,064 (318.18) Ref. 6254 (161.51) Ref. 3810 (156.67) Ref.
Users 272 (11.05) 1.31 (1.16–1.48) 83 (2.27) 1.24 (1.00–1.54) 189 (8.78) 1.44 (1.24–1.66)
p-value† b0.001 0.02 b0.001
a Adjusted for sex, income, and education the year before the stroke and for age (restricted cubic spline, four knots) and calendar year the year of stroke.
b Adjusted for income and education the year before the stroke and for age (restricted cubic spline, four knots) and calendar year the year of stroke.
† Test for effect modiﬁcation in risk of stroke with respect to triptan use, i.e. ischemic stroke VS hemorrhagic stroke and among stroke severity categories.
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strokes while severe strokes were less prevalent.
4.1. Stroke Risk Factor Proﬁle
The prevalence of risk factors for stroke among stroke patients who
used triptans was markedly lower than among stroke patients who did
not use triptans. This might reﬂect caution by Danish doctors in pre-
scribing triptans for patients with cardiovascular risk factors. The fact
that patients with risk factors nevertheless received prescriptions for
triptans may indicate a risk–beneﬁt decision. Alternatively, the etiology
of strokes in triptan users may differ from that of non-users (with a dif-
ferent risk factor proﬁle) whichmight suggest a different kind of stroke
etiology for triptan users i.e. migraineurs. We had information on the
cardiovascular risk factor proﬁles only for those with stroke; however,
the markedly lower age-adjusted prevalence in users of triptans speaks
against a higher prevalence of cardiovascular risk factors as the underly-
ing cause of the increased risk for stroke of triptan users. Use of contra-
ceptive pills was the same in users and non-users of triptans and did notFig. 2. Relative risks and conﬁdence intervals for all stroke types for the interaction between
population (a), p-value for interaction is 0·073; for female population (b), p-value for interactinﬂuence the effect of triptans. Furthermore, the risk for stroke among
triptans users was increased for both sexes.
4.2. Cause of Stroke: Triptans vs Migraine
In Denmark, triptans are registered only for the treatment of mi-
graine and cluster headache. As the prevalence of cluster headache is
considerably lower than that of migraine, particularly among women
(Manzoni and Stovner, 2010), our population of triptan users can be
considered as a group of patients with migraine. We found that risk of
stroke among triptan users was unrelated to numbers of prescriptions
dispensed. Reports on strokes directly related to intake of triptans are
rare (Roberto et al., 2015). Thus, overrepresentation of stroke in triptan
users in our study seems more likely to be the result of the underlying
migraine disorder rather than use of triptans. As a result of the
vasoconstricting effect of triptans the question of a possible association
between the use of triptans and stroke comes up regularly since the
number of users is high (5% of Danish women between 25 and
80 years; 7.5% of Danish women aged 45–50 years). Although thetriptan (users versus non-users) and age modeled with restricted cubic spline. For male
ion is b0.0001.
Table 3
Risk factors for stroke with respect to triptan use.
All
Non-users (%)
All
Users (%)
Men
Non-users (%)
Men
Users (%)
Women
Non-users (%)
Women
Users (%)
⁎Alcohol ≤14/21 drinks per week 38,302 (78.76) 942 (86.90) 21,846 (76.18) 276 (84.15) 16456 (82.47) 666 (88.10)
N14/21 drinks per week 4965 (10.21) 47 (4.34) 4000 (13.95) 23 (7.01) 965 (4.84) 24 (3.17)
Missing data 5362 (11.03) 95 (8.76) 2,830 (9.87) 29 (8.84) 2532 (12.69) 66 (8.73)
Smoking Daily smokers 19,502 (40.10) 395 (36.44) 12,101 (42.20) 133 (40.55) 7401 (37.09) 262 (34.66)
Occasionally smokers 591 (1.22) 15 (1.38) 369 (1.29) 7 (2.13) 222 (1.11) 8 (1.06)
Former smokers 9664 (19.87) 181 (16.70) 6566 (22.9) 59 (17.99) 3098 (15.53) 122 (16.14)
Never smokers 13,065 (26.87) 374 (34.50) 6528 (22.76) 97 (29.57) 6537 (32.76) 277 (36.64)
Missing data 5807 (11.94) 119 (10.98) 3112 (10.85) 32 (9.76) 2695 (13.51) 87 (11.51)
Diabetes Yes 6329 (13.01) 75 (6.92) 4091 (14.27) 25 (7.62) 2238 (11.22) 50 (6.61)
No 41,510 (85.36) 997 (91.97) 24,120 (84.11) 298 (90.85) 17,390 (87.15) 699 (92.46)
Missing data 790 (1.62) 12 (1.11) 465 (1.62) 5 (1.52) 325 (1.63) 7 (0.93)
Atrial ﬁbrillation Yes 5157 (10.60) 68 (6.27) 3013 (10.51) 21 (6.4) 2144 (10.75) 47 (6.22)
No 42,493 (87.38) 1000 (92.25) 25,081 (87.46) 300 (91.46) 17,412 (87.27) 700 (92.59)
Missing data 979 (2.01) 16 (1.48) 582 (2.03) 7 (2.13) 397 (1.99) 9 (1.19)
Prev. myocardial infarct Yes 3746 (7.70) 36 (3.32) 2740 (9.56) 12 (3.66) 1006 (5.04) 24 (3.17)
No 43,883 (90.24) 1035 (95.48) 25,349 (88.40) 310 (94.51) 18,534 (92.89) 725 (95.90)
Missing data 1000 (2.06) 13 (1.20) 587 (2.05) 6 (1.83) 413 (2.07) 7 (0.93)
Hypertension Yes 22,509 (46.29) 433 (39.94) 13,119 (45.75) 131 (39.94) 9390 (47.06) 302 (39.95)
No 24,737 (50.87) 621 (57.29) 14,711 (51.30) 186 (56.71) 10,026 (50.25) 435 (57.54)
Missing data 1383 (2.84) 30 (2.77) 846 (2.95) 11 (3.35) 537 (2.69) 19 (2.51)
Claudication Yes 1317 (2.71) 13 (1.20) 851 (2.97) 5 (1.52) 466 (2.34) 8 (1.06)
No 38,761 (79.71) 899 (82.93) 22,798 (79.5) 277 (84.45) 15,963 (80) 622 (82.28)
Missing data 8551 (17.58) 172 (15.87) 5027 (17.53) 46 (14.02) 3524 (17.66) 126 (16.67)
Total 48,629 1084 28,676 328 19,953 756
⁎ The maximum limit set by the Danish National Board of Health: 14 drinks per week for women and 21 for men.
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1.07 it was increased RR 1.7 amongwomen aged 25–45 years of age and
the incidence of stroke in the triptan using part of the population was
not negligible (1.36 per 1000 per year). Our study therefore conﬁrms
that any prescription of triptans for headaches should be preceded by
careful considerations of the risk for stroke, especially in patients with
stroke risk factors.
As the population not prescribed triptans also includes people with
migraine who do not need triptans, our study may indicate a risk for
stroke only when migraine is severe. If the increased risk for stroke in
triptan users reﬂects an increased risk for stroke among patients with
migraine, the risk estimates in our study would be biased towards the
null.
4.3. Migraine and Stroke
Increased risk for ischemic stroke in migraine have been document-
ed in several meta-analyses (Etminan et al., 2005; Schurks et al., 2009;
Spector et al., 2010), as in our study. An increased risk for hemorrhagic
stroke was also reported in a recent meta-analysis (Sacco et al., 2013);
however, the correlation was found only for women, as the number of
men in the analysis did not provide sufﬁcient statistical power. The
samewas true of our study. Little information is available on the relation
between severity of stroke and migraine. In theWomen's Health Study,
strokes in twenty-twowomenwithmigrainewith aurawere associatedTable 4
Prevalence (%) of risk factors with respect to triptan use adjusted by age (overall and by sex) f
All non-users All users pb Male non-us
Alcohola 9.28 4.84 b0.001 13.08
Smoking⁎⁎⁎ 56.10 47.15 b0.001 62.72
Diabetes 13.87 7.43 b0.001 15.20
Atrial ﬁbrillation 14.06 10.58 b0.001 13.58
Previous myocardial infarct 9.30 4.41 b0.001 11.58
Hypertension 51.16 48.49 0.09 49.77
Claudication 3.79 1.83 b0.001 4.12
a Alcohol consumption over the limit set by the Danish National Board of Health: 14 drinks
b Difference in prevalence between triptan users and non-users.
⁎⁎⁎ Only current smokers (i.e. daily and occasional smokers) were considered.signiﬁcantly more often with a good outcome (Rist et al., 2010). The
authors raised the question of whether stroke in migraine patients is
different from atherosclerosis and instead speciﬁcally involves micro-
vascular phenomena. The results of our study raise the same question.
In our study, the 1084migraineurs identiﬁed through triptan utilization
were at increased risk for minor strokes but at signiﬁcantly reduced risk
for major strokes in comparisonwith people not using triptans. The risk
for stroke among triptan users was particularly high among women
aged 25–40 years, and the risk decreased rapidly with age. This may
well be due to the fact that atheromatosis-related risk factors are less
frequent in young people, so that strokes with another etiology more
easily become signiﬁcant in statistical analyses. As discussed previously,
the markedly lower prevalence of cardiovascular risk factors might also
be interpreted as an expression of a different kind of stroke etiology
among migraineurs. Our study thus provides further evidence of a bio-
logical mechanism for stroke associated with migraine that is different
from the mechanisms associated with atheromatosis.
Various causes have been proposed for the higher incidence of
stroke in patientswithmigraine (Kurth andDiener, 2012). Some studies
reported a higher incidence of cardiovascular risk factors in patients
with migraine, although the elevated risk remained after control for
these factors (Kurth and Diener, 2012). In our study prevalence of
cardiovascular risk factors were lower among stroke patients with mi-
graine using triptans than among stroke patients at comparable age
not using triptans. Several studies indicate that the increased risk foror patients with stroke.
ers Male users pb Female non-users Female users pb
8.61 0.01 4.18 2.97 0.07
55.74 0.03 47.78 42.34 0.01
7.84 b0.001 12.22 7.30 b0.001
10.40 0.06 14.87 11.25 b0.01
4.41 b0.001 6.31 4.33 0.01
44.34 0.05 53.01 50.87 0.25
1.80 b0.01 3.35 1.85 0.01
per week for women and 21 for men.
204 V. Albieri et al. / EBioMedicine 6 (2016) 199–205stroke is present only when migraine is associated with aura (Schurks
et al., 2009). Studies of brain blood ﬂow during migraine auras have
shown focal reduction of cerebral blood ﬂow consistent with ischemia
(Olsen et al., 1987; Olsen and Lassen, 1989). Thus, migraine patients
with aura may develop ischemia at the microvascular level, which,
under some conditions, manifests as a minor stroke. The design of our
study did not allow us to distinguish between migraine with and with-
out aura;wewere therefore unable to determinewhether the increased
risk of migraine patients for stroke is associated with both types of mi-
graine or only with migraine with aura. The increased risk for hemor-
rhagic stroke among migraineurs using triptans in this study and in
other studies on migraine and stroke remains to be explained (Kurth
and Tzourio, 2013). Suggestions such as altered platelet or endothelial
function, use of non-steroidal anti-inﬂammatory drugs for migraine at-
tacks and structural brain lesions or malformations giving rise to head-
ache mimicking migraine are still hypothetical (Sacco et al., 2013).
4.4. Strengths and Limitations
A major strength of this study was the large dataset, with informa-
tion on age, sex, disposable income, and length of education for the
entire Danish population (5.5 million). Furthermore, the personal
identiﬁcation number allowed linkage to the Danish Registry of Pre-
scriptions and to the Danish Stroke Registry, which covers patients hos-
pitalized for stroke in Denmark since 2003. The hospitalization rate
according to the registry is high (2.3 per 1000/year) (Andersen et al.,
2014) and registration in the Registry has high validity (Wildenschild
et al., 2013). The completeness of the data on diabetes, previous myo-
cardial infarction, atrial ﬁbrillation, and hypertension for patients regis-
tered with a stroke in this register was N87%; for alcohol consumption,
smoking, and intermittent claudication completeness was N83%. Infor-
mation on stroke severity on hospital admission was available for 80%
of patients. Therefore, we consider that our study populationwas repre-
sentative of both the Danish population of migraineurs prescribed
triptans and the Danish population hospitalized for stroke.
A weakness of the study was the lack of information on headache
and migraine type nor did we have exact information on the predictive
value of using triptan utilization as a proxy for migraine. However, as
triptans are licensed in Denmark only for migraine (and cluster head-
ache, as discussed above) and need prescription by an authorized
physician,we consider it highly likely that the populationwith prescrip-
tions for triptans represents a migraine population. The population
without prescriptions for triptans includes patients with migraine not
using triptans. If, as previously mentioned, the increased risk for stroke
in triptan users reﬂects an increased risk for stroke among patients with
migraine, the risk estimates in our study would be biased towards the
null.
Users and non-users of triptans may differ according to use of con-
comitant analgesic agents such as aspirin, paracetamol and NSAID's
(non-steroidal anti-inﬂammatory drugs). As a number of these drugs
are delivered over-the-counter they cannot be tracked in the register
of prescriptions and cannot be adjusted for in our model. Paracetamol
does not inﬂuence risk of stroke (García-Poza et al., 2015). Aspirin
lowers risk of ischemic stroke but may increase risk of hemorrhagic
stroke (Gorelick and Weisman, 2005). While some of the NSAID's ap-
pear to increase the risk of stroke, NSAID's as a group do not increase
signiﬁcantly the risk for stroke (García-Poza et al., 2015; Coxib and
traditional NSAID Trialists' (CNT) Collaboration, 2013). So even if an ef-
fect of these drugs cannot be excluded it will hardly be of a magnitude
that it is going to change our conclusions especially regarding ischemic
stroke. As N90% of patients with acute stroke are hospitalized in
Denmark (Jørgensen et al., 1992), our observations apply to the major-
ity of stroke patients but only to thosewho are hospitalized. The Danish
Stroke Registry does not include transient ischemic attacks. As the risk
ofmigraineurs prescribed triptans in our studywas forminor stroke, in-
clusion of transient ischemic attacks in the analysis would have beendesirable. As another proxy for migraine usage of ergotamine was con-
sidered. However, the use of ergotamine in Denmark is so small (0.15%
of all Danes have used ergotamine within a 5-year period compared to
approx. 4.6% for triptans (i.e. 30 times more frequent)) that it does not
serve as a valid comparison.
5. In Conclusion
Migraineurs using triptans are at increased risk for both ischemic
and hemorrhagic stroke. The excess risk did not seem to be related to
the use of triptans as such; instead, our study points to the underlying
migraine disease as the cause of the increased risk of stroke among
migraineurs. Strokes in migraineurs differed from those of the general
stroke population by being less severe and associated with lower prev-
alence of cardiovascular risk factors. Thus, our study suggests an etiolo-
gy of stroke in migraineurs different from that of atherosclerotic
thromboembolism, probably at the microvascular level. Whatever the
cause, stroke is a serious incident in young people undergoing treat-
ment for a disorder that is usually not perceived dangerous. Therefore,
our study underlines the necessity of making a careful risk assessment
before prescribing triptans for the treatment of headaches. If, as indicat-
ed in this study, migraine is associated with an etiology of stroke differ-
ent from thromboembolism this may have clinical implications for this
(although smaller) part of the stroke population in regard to both
acute treatment (thrombolytics) and secondary prevention (platelet ag-
gregation inhibitors, statins). More studies are warranted.
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